CN114306285A - 地氯雷他定口腔速溶膜及其制备方法 - Google Patents
地氯雷他定口腔速溶膜及其制备方法 Download PDFInfo
- Publication number
- CN114306285A CN114306285A CN202011059718.XA CN202011059718A CN114306285A CN 114306285 A CN114306285 A CN 114306285A CN 202011059718 A CN202011059718 A CN 202011059718A CN 114306285 A CN114306285 A CN 114306285A
- Authority
- CN
- China
- Prior art keywords
- desloratadine
- film
- agent
- oral instant
- orally disintegrating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 title claims abstract description 69
- 229960001271 desloratadine Drugs 0.000 title claims abstract description 69
- 238000002360 preparation method Methods 0.000 title abstract description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 15
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract description 15
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 15
- 239000011718 vitamin C Substances 0.000 claims abstract description 15
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 15
- 239000000463 material Substances 0.000 claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 239000004014 plasticizer Substances 0.000 claims abstract description 12
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 10
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 10
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 10
- 239000003086 colorant Substances 0.000 claims abstract description 8
- 239000000796 flavoring agent Substances 0.000 claims abstract description 8
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 36
- 229920002472 Starch Polymers 0.000 claims description 13
- 239000008107 starch Substances 0.000 claims description 13
- 235000019698 starch Nutrition 0.000 claims description 13
- 239000002202 Polyethylene glycol Substances 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000000499 gel Substances 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- 229940083542 sodium Drugs 0.000 claims description 9
- 229910052708 sodium Inorganic materials 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 7
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 claims description 6
- 239000011521 glass Substances 0.000 claims description 6
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- 229940023476 agar Drugs 0.000 claims description 4
- 235000010419 agar Nutrition 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 229960002900 methylcellulose Drugs 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 229940045110 chitosan Drugs 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 claims description 3
- 229960001826 dimethylphthalate Drugs 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 abstract description 16
- 239000000126 substance Substances 0.000 abstract description 13
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 210000004379 membrane Anatomy 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 8
- 229920000858 Cyclodextrin Polymers 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 239000004376 Sucralose Substances 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 235000019408 sucralose Nutrition 0.000 description 6
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- -1 polyoxyethylene Polymers 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 235000016068 Berberis vulgaris Nutrition 0.000 description 3
- 241000335053 Beta vulgaris Species 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 3
- 229960003088 loratadine Drugs 0.000 description 3
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- CUJVBAPGYBSBHJ-YWBSARSQSA-N 2-[[(1R,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21R,23R,25R,26R,28R,30R,31R,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-36,38,40,42-tetrakis(carboxymethoxy)-10,15-bis(carboxymethoxymethyl)-37,39,41,43,44,45,46,47,48,49-decahydroxy-20,25,30,35-tetrakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methoxy]acetic acid Chemical compound OC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@H]1[C@H](OCC(O)=O)[C@H]2O)[C@H](O)[C@H]5OCC(O)=O)[C@H](O)[C@H]4OCC(O)=O)[C@H](O)[C@H]3OCC(O)=O CUJVBAPGYBSBHJ-YWBSARSQSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 239000009627 gardenia yellow Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种地氯雷他定口腔速溶膜及其制备方法,口腔速溶膜包含的组分及各组分的质量百分含量如下:地氯雷他定2.5%~10%、抗氧剂3%~25%、成膜材料25%~70%、增塑剂5%~20%、崩解剂2~10%、矫味剂0%~2%、着色剂0%~1%,余量水和乙醇;所述抗氧剂为EDTA‑2Na和维生素C的组合物。本发明的地氯雷他定口腔速溶膜中包含抗氧剂EDTA‑2Na和维生素C;这两种物质的添加,显著地提高了地氯雷他定口腔速溶膜的稳定性;本发明的地氯雷他定口腔速溶膜使用的均是水溶剂的辅料,在保证膜剂稳定性的前提下,制备工艺简单,适合工业化大生产。
Description
技术领域
本发明涉及地氯雷他定的剂型,具体涉及一种地氯雷他定口腔速溶膜及其制备方法。
背景技术
目前地氯雷他定的主要剂型为片剂、胶囊、糖浆和干混悬。由于片剂、胶囊和干混悬为固体制剂,起效慢,且需用水服用,儿童、老年人和吞咽困难者服用都存在一定的困难;糖浆剂虽然起效快,但服用和携带均不方便。
口腔速溶膜剂(Oral Fast Dissolving Films)是一种近年来被广泛应用的口服固体速释新剂型,入口即化,其中的药物有效成分快速释放,被口腔黏膜及食管组织吸收而进入血液;另外,口腔速溶膜剂方便携带,入口方式适用于各种人群。
中国专利文献CN106619577A(申请号 201610883918.4)公开了一种新型氯雷他定口腔速溶膜,口腔速溶膜包括氯雷他定、表面活性剂、成膜材料、调味剂、矫味剂及少量乙醇。所述表面活性剂为聚山梨醇酯80、豆磷脂、卵磷脂、十二烷基硫酸钠、泊洛沙姆188、泊洛沙姆407、十二烷基磺酸钠、阿拉伯胶、聚氧乙烯脂肪醇醚、聚氧乙烯烷基酚醚、二辛基琥珀酰磺酸钠、月桂醇硫酸钠、明胶、皂甙、胆甾醇、聚氧乙烯蓖麻油衍生物、单硬脂肪酸甘油脂、海藻酸钠中的一种或一种以上的混合物。所述成膜材料为聚氧乙烯、淀粉、琼脂、五卡波树脂、甲基纤维素、乙基纤维素、羟丙甲纤维素、羟丙基纤维素、丙 烯酸树脂、玉米朊、黄原胶、阿拉伯胶、聚乙烯醇、乙烯-醋酸乙烯共聚物中的一种或一种以上的混合物。上述口腔速溶膜制备时使用高速分散器和高压均质机将水油两相分散均匀,操作复杂,成本较高;处方中使用磷脂类表面活性剂时,所得制品存储条件要求高。
中国专利文献CN 105616389A(申请号 201610213587.3)公开了一种枸地氯雷他定口腔速溶膜及其制备方法,包括以下各组分:枸地氯 雷他定、成膜材料、环糊精、增塑剂、矫味剂、pH调节剂和着色剂。所述环糊精选自α-环糊精、β-环糊精、γ-环糊精、羧甲基-β-环糊精、羟丙基-β-环糊 精或磺丁基醚-β-环糊精中的任意一种或任意多种按照任意比例组成的混合物。该专利中用到环糊精包合技术,虽然能保证枸地氯雷他定的稳定性,但由于环糊精包合技术较难,包封率的检测复杂,这些都导致工业生产受限。
发明内容
本发明所要解决的技术问题是提供一种稳定性好的地氯雷他定口腔速溶膜,及其工艺简单的制备方法。
实现本发明第一目的的技术方案是一种地氯雷他定口腔速溶膜,包含的组分及各组分的质量百分含量如下:地氯雷他定2.5%~10%、抗氧剂3%~25%、成膜材料25%~70%、增塑剂5%~20%、崩解剂2~10%、矫味剂0%~2%、着色剂0%~1%,余量水和乙醇;所述抗氧剂为EDTA-2Na和维生素C的组合物。
上述地氯雷他定口腔速溶膜中水分含量9%~11%。
作为优选的,EDTA-2Na和维生素C的质量比为1~3:1。
所述成膜材料为甲基纤维素、乙基纤维素、羟丙基纤维素、羟丙甲基纤维素、聚乙烯醇、透明质酸、琼脂、黄原胶、瓜尔胶、壳聚糖、海藻酸钠中的一种或一种以上的组合物。
所述增塑剂为甘油、丙二醇、聚乙二醇、山梨醇、甘露糖醇、邻苯二甲酯类中的一种或一种以上的组合物。
作为优选的,增塑剂为丙二醇和聚乙二醇的组合物。
所述崩解剂为淀粉、预胶化淀粉、羧甲基淀粉钠、低取代羟丙纤维素、交联聚乙烯比咯烷酮中的一种或一种以上的组合物。
作为优选的,崩解剂为羧甲基淀粉钠。
实现本发明第二目的的技术方案是上述地氯雷他定口腔速溶膜的制备方法,包括以下步骤:
①称取处方量的地氯雷他定,加入乙醇的水溶液中,室温搅拌溶解。
②向步骤①得到的溶液中加入处方量的EDTA-2Na、维生素C、矫味剂和着色剂,室温搅拌溶解。
③称取处方量的成膜材料、增塑剂和崩解剂,加到步骤②得到的溶液中,搅拌分散均匀并静置。
④将步骤③得到的凝胶倾倒在玻璃板上,用推杆调至适宜的厚度,在40℃~55℃下烘干1~3小时。
⑤将烘干后的膜从玻璃板上剥离,裁剪后密封包装。
上述步骤③中静置8~14小时。
本发明具有积极的效果:
(1)本发明的地氯雷他定口腔速溶膜中包含抗氧剂EDTA-2Na和维生素C;这两种物质的添加,显著地提高了地氯雷他定口腔速溶膜的稳定性;溶出试验中,本发明的地氯雷他定口腔速溶膜的有关物质总杂含量最低,且15min溶出累计数值最高。
(2)本发明的地氯雷他定口腔速溶膜使用的均是水溶剂的辅料,在保证膜剂稳定性的前提下,相比要进行水油两相分散、以及环糊精包合的技术方案,制备工艺简单,适合工业化大生产。
具体实施方式
下面介绍的是本发明的多个可能实施例中的一些,旨在提供对本发明的基本了解,并不旨在确认本发明的关键或决定性的要素或限定所要保护的范围。容易理解,根据本发明的技术方案,在不变更本发明的实质精神下,本领域的一般技术人员可以提出可相互替换的其他实现方式。因此,以下具体实施方式仅是对本发明的技术方案的示例性说明,而不应当视为本发明的全部或者视为对本发明技术方案的限定或限制。
本发明的地氯雷他定口腔速溶膜包含的组分及各组分的质量百分含量如下:地氯雷他定2.5%~10%、抗氧剂3%~25%、成膜材料25%~70%、增塑剂5%~20%、崩解剂2~10%、矫味剂0%~2%、着色剂0%~1%,余量水和乙醇;地氯雷他定口腔速溶膜中水分含量9%~11%。
所述抗氧剂为EDTA-2Na和维生素C的组合物,EDTA-2Na和维生素C的质量比为1~3:1。
所述成膜材料为甲基纤维素、乙基纤维素、羟丙基纤维素、羟丙甲基纤维素、聚乙烯醇、透明质酸、琼脂、黄原胶、瓜尔胶、壳聚糖、海藻酸钠中的一种或一种以上的组合物。
所述增塑剂为甘油、丙二醇、聚乙二醇、山梨醇、甘露糖醇、邻苯二甲酯类中的一种或一种以上的组合物。
所述崩解剂为淀粉、预胶化淀粉、羧甲基淀粉钠、低取代羟丙纤维素、交联聚乙烯比咯烷酮中的一种或一种以上的组合物。
所述矫味剂为蔗糖、果糖、阿司帕坦、山梨醇、木糖醇、甜蜜素、甘草甜素、糖精中的一种或一种以上的组合物。
所述着色剂为甜菜红、胡萝卜素、焦糖色素、姜黄、栀子黄、藻蓝素中的一种。
(实施例1)
本实施例的地氯雷他定口腔速溶膜每片含地氯雷他定5mg,制备1000片地氯雷他定口腔速溶膜的配方如下:地氯雷他定 5g,EDTA-2Na 10g,维生素C 4g,羟丙基纤维素 20g,丙二醇2g,聚乙二醇 2g,羧甲基淀粉钠4g,三氯蔗糖 1g,纯化水 200g,1mL乙醇。
本实施例的地氯雷他定口腔速溶膜的制备方法包括以下步骤:
①称取处方量的地氯雷他定,加入乙醇的水溶液中,室温(10℃~35℃)搅拌溶解。
②向步骤①得到的溶液中加入处方量的EDTA-2Na、维生素C、三氯蔗糖和甜菜红,室温搅拌溶解。
③称取处方量的羟丙基纤维素、丙二醇、聚乙二醇和羧甲淀粉钠,加到步骤②得到的溶液中,搅拌分散均匀,并静置过夜(静置8~14小时)。
④将步骤③得到的凝胶倾倒在玻璃板上,用推杆调至适宜的厚度,在40℃~55℃下烘干1~3小时;本实施例中在50℃下烘2小时。
⑤将烘干后的膜从玻璃板上剥离,裁剪后密封包装。
外观评价:本实施例制得的地氯雷他定口腔速溶膜外观良好,半透明,无颗粒感无气泡,柔韧性较好,口感较好。
理化性能评测:水分测定9.3%,溶化时限30s;pH1.0的盐酸溶液,15min溶出累计达94.7%,有关物质总杂为0.11%。
(实施例2)
本实施例的地氯雷他定口腔速溶膜每片含地氯雷他定5mg,制备1000片地氯雷他定口腔速溶膜的配方如下:地氯雷他定 5g,EDTA-2Na 5g,维生素C 5g,羟丙基纤维素 20g,丙二醇2g,聚乙二醇 2g,羧甲基淀粉钠4g,三氯蔗糖 1g,甜菜红 0.5g,纯化水 200g,1mL乙醇。
制备方法参考实施例1。
对本实施例制得的地氯雷他定口腔速溶膜评测如下:
外观评价:外观良好,半透明,无颗粒感无气泡,柔韧性较好,口感较好。
理化性能评测:水分测定10.2%,溶化时限32s;pH1.0的盐酸溶液,15min溶出累计达93.0%,有关物质总杂为0.13%。
(对比例1)
本对比例的地氯雷他定口腔速溶膜每片含地氯雷他定5mg,制备1000片地氯雷他定口腔速溶膜的配方如下:
地氯雷他定 5g,羟丙基纤维素 38g,丙二醇2g,聚乙二醇 2g,三氯蔗糖 1g,纯化水200g,1mL乙醇。
制备方法参考实施例1。
对本对比例制得的地氯雷他定口腔速溶膜评测如下:
外观评价:外观良好,半透明,无颗粒感无气泡,柔韧性较好,口感较好。
理化性能评测:水分测定10.4%,溶化时限57s;pH 1.0的盐酸溶液,15min溶出累计达90.7%,有关物质总杂为0.30%。
(对比例2)
本对比例的地氯雷他定口腔速溶膜每片含地氯雷他定5mg,制备1000片地氯雷他定口腔速溶膜的配方如下:
地氯雷他定 5g,EDTA-2Na 14g,羟丙基纤维素24g,丙二醇2g,聚乙二醇 2g,三氯蔗糖1g,纯化水 200g,1mL乙醇。
对本对比例制得的地氯雷他定口腔速溶膜评测如下:
外观评价:外观良好,半透明,无颗粒感无气泡,柔韧性较好,口感较好。
理化性能评测:水分测定10.3%,溶化时限54s;pH1.0的盐酸溶液,15min溶出累计达89.8%,有关物质总杂为0.19%。
(对比例3)
本对比例的地氯雷他定口腔速溶膜每片含地氯雷他定5mg,制备1000片地氯雷他定口腔速溶膜的配方如下:
地氯雷他定 5g,维生素C 14g,羟丙基纤维素24g,丙二醇2g,聚乙二醇 2g,三氯蔗糖1g,纯化水 200g,1mL乙醇。
对本对比例制得的地氯雷他定口腔速溶膜评测如下:
外观评价:外观良好,半透明,无颗粒感无气泡,柔韧性较好,口感较好。
理化性能评测:水分测定11%,溶化时限51s;pH 1.0的盐酸溶液,15min溶出累计达91.3%,有关物质总杂为0.18%。
Claims (10)
1.一种地氯雷他定口腔速溶膜,其特征在于包含的组分及各组分的质量百分含量如下:地氯雷他定2.5%~10%、抗氧剂3%~25%、成膜材料25%~70%、增塑剂5%~20%、崩解剂2~10%、矫味剂0%~2%、着色剂0%~1%,余量水和乙醇;所述抗氧剂为EDTA-2Na和维生素C的组合物。
2.根据权利要求1所述的地氯雷他定口腔速溶膜,其特征在于:地氯雷他定口腔速溶膜中水分含量9%~11%。
3.根据权利要求1所述的地氯雷他定口腔速溶膜,其特征在于:EDTA-2Na和维生素C的质量比为1~3:1。
4.根据权利要求1所述的地氯雷他定口腔速溶膜,其特征在于:所述成膜材料为甲基纤维素、乙基纤维素、羟丙基纤维素、羟丙甲基纤维素、聚乙烯醇、透明质酸、琼脂、黄原胶、瓜尔胶、壳聚糖、海藻酸钠中的一种或一种以上的组合物。
5.根据权利要求1所述的地氯雷他定口腔速溶膜,其特征在于:所述增塑剂为甘油、丙二醇、聚乙二醇、山梨醇、甘露糖醇、邻苯二甲酯类中的一种或一种以上的组合物。
6.根据权利要求5所述的地氯雷他定口腔速溶膜,其特征在于:所述增塑剂为丙二醇和聚乙二醇的组合物。
7.根据权利要求1所述的地氯雷他定口腔速溶膜,其特征在于:所述崩解剂为淀粉、预胶化淀粉、羧甲基淀粉钠、低取代羟丙纤维素、交联聚乙烯比咯烷酮中的一种或一种以上的组合物。
8.根据权利要求7所述的地氯雷他定口腔速溶膜,其特征在于:所述崩解剂为羧甲基淀粉钠。
9.一种如权利要求1所述的地氯雷他定口腔速溶膜的制备方法,其特征在于包括以下步骤:
①称取处方量的地氯雷他定,加入乙醇的水溶液中,室温搅拌溶解;
②向步骤①得到的溶液中加入处方量的EDTA-2Na、维生素C、矫味剂和着色剂,室温搅拌溶解;
③称取处方量的成膜材料、增塑剂和崩解剂,加到步骤②得到的溶液中,搅拌分散均匀并静置;
④将步骤③得到的凝胶倾倒在玻璃板上,用推杆调至适宜的厚度,在40℃~55℃下烘干1~3小时;
⑤将烘干后的膜从玻璃板上剥离,裁剪后密封包装。
10.根据权利要求9所述的地氯雷他定口腔速溶膜的制备方法,其特征在于:步骤③中静置8~14小时。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011059718.XA CN114306285B (zh) | 2020-09-30 | 2020-09-30 | 地氯雷他定口腔速溶膜及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011059718.XA CN114306285B (zh) | 2020-09-30 | 2020-09-30 | 地氯雷他定口腔速溶膜及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114306285A true CN114306285A (zh) | 2022-04-12 |
CN114306285B CN114306285B (zh) | 2024-05-14 |
Family
ID=81011409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011059718.XA Active CN114306285B (zh) | 2020-09-30 | 2020-09-30 | 地氯雷他定口腔速溶膜及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114306285B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060210610A1 (en) * | 2002-11-14 | 2006-09-21 | Davidson Robert S | Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use |
JP2008169138A (ja) * | 2007-01-11 | 2008-07-24 | Tsukioka:Kk | フィルム状製剤及びフィルム状製剤の製造方法 |
CN102940617A (zh) * | 2012-11-21 | 2013-02-27 | 北京润德康医药技术有限公司 | 一种地氯雷他定口腔分散膜剂 |
CN104958295A (zh) * | 2015-06-17 | 2015-10-07 | 天津市聚星康华医药科技有限公司 | 一种用于过敏性鼻炎的复方药物组合物 |
CN105616389A (zh) * | 2016-04-06 | 2016-06-01 | 合肥华方医药科技有限公司 | 一种枸地氯雷他定口腔速溶膜及其制备方法 |
-
2020
- 2020-09-30 CN CN202011059718.XA patent/CN114306285B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060210610A1 (en) * | 2002-11-14 | 2006-09-21 | Davidson Robert S | Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use |
JP2008169138A (ja) * | 2007-01-11 | 2008-07-24 | Tsukioka:Kk | フィルム状製剤及びフィルム状製剤の製造方法 |
CN102940617A (zh) * | 2012-11-21 | 2013-02-27 | 北京润德康医药技术有限公司 | 一种地氯雷他定口腔分散膜剂 |
CN104958295A (zh) * | 2015-06-17 | 2015-10-07 | 天津市聚星康华医药科技有限公司 | 一种用于过敏性鼻炎的复方药物组合物 |
CN105616389A (zh) * | 2016-04-06 | 2016-06-01 | 合肥华方医药科技有限公司 | 一种枸地氯雷他定口腔速溶膜及其制备方法 |
Non-Patent Citations (2)
Title |
---|
任连杰等: "口腔膜剂的研发与评价", 中国中药杂志, vol. 42, no. 19, pages 3696 - 3702 * |
荆云梅: "地氯雷他定口腔速溶膜的研制", 硕士电子期刊, no. 4, pages 1 - 50 * |
Also Published As
Publication number | Publication date |
---|---|
CN114306285B (zh) | 2024-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8911769B2 (en) | Orally disintegrating pharmaceutical composition comprising diclofenac | |
Satyanarayana et al. | Fast disintegrating films containing anastrozole as a dosage form for dysphagia patients | |
EP2804596B1 (en) | Transmucosal administration system for a pharmaceutical drug | |
EP2893940A2 (en) | Granulated material for tablet that rapidly disintegrates in mouth | |
EP0018773B1 (en) | A pharmaceutical composition containing bencyclane fumarate, a process for its preparation and an inclusion compound containing bencyclane fumarate | |
CN106176685A (zh) | 一种包含他达拉非的口溶膜剂及其制备方法 | |
WO2015115453A1 (ja) | 口腔内速崩壊性固形製剤用組成物 | |
US20230338320A1 (en) | Oral film composition comprising levothyroxine | |
CN115867351A (zh) | Hiv药物的口腔膜 | |
Sabar | Formulation and in vitro evaluation of fast dissolving film containing amlodipine besylate solid dispersion | |
ES2211844T3 (es) | Composicion farmaceutica de un derivado de quinolinona y procedimiento de produccion de la misma. | |
CN114306285B (zh) | 地氯雷他定口腔速溶膜及其制备方法 | |
Saeed et al. | Effect of natural/synthetic polymers and super disintegrants on the formulation of zafirlukast fast dissolving film | |
Kiran et al. | A mini review on buccal films an innovative dosage form | |
CN106074456A (zh) | 一种苯磺酸氨氯地平口腔速溶膜及其制备方法 | |
WO2021029631A1 (ko) | 대마의 오일 추출물 또는 파우더 추출물을 제제의 원료로 함유하는 구강 내 속붕해 제제 | |
CN105919982A (zh) | 一种消旋卡多曲口腔速溶膜及其制备方法 | |
CN105963264A (zh) | 一种地氯雷他定舌下片及其制备方法 | |
Chavan et al. | Indian Journal of Pharmaceutical Science & Research | |
CN106963739A (zh) | 泼尼松龙口腔崩解片及其制备方法 | |
Bhalse et al. | A REVIEW ON MOUTH DISSOLVING FILM | |
Mahdi et al. | The development and characterization of a new easily swallowed valsartan oral jelly | |
KR20230120924A (ko) | 유단백가수분해물을 포함하는 구강붕해필름 | |
Gautam et al. | ORODISPERSIBLE FILMS: AN AVANT-GARDE WATER FREE DRUG DELIVERY | |
Albadri et al. | Preparation and in vitro characterization of pediatric fast dissolving strip of dexchlorpheniramine maleate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |